非酒精性脂肪性肝病的医疗成本与资源利用:来自美国大型理赔数据库的真实世界数据
本研究利用覆盖逾1亿人的OptumLabs Data Warehouse理赔数据库,纳入2010—2014年首次诊断为非酒精性脂肪性肝病(NAFLD)的152,064名成人,其中108,420人按年龄、性别、代谢共病、随访时长、诊断年份、种族、地区和保险类型与无NAFLD对照1:1匹配。结果显示,NAFLD患者初次诊断当年人均年总费用为7,804美元,长期管理为3,789美元,均显著高于匹配对照的2,298美元;费用增加主要来自肝活检、影像检查和住院。
要点
- NAFLD初次诊断当年人均年总费用为7,804美元,长期管理为3,789美元,匹配对照为2,298美元。
- 费用差异主要来自肝活检(RR=55.00)、影像检查(RR=3.95)和住院(RR=1.87)。
- 作者认为应研究费用升高的决定因素和超额费用来源,并开发具有成本效益的诊断检查。
核心结论
- NAFLD相关医疗费用即使独立于其代谢共病也非常高,尤其在首次诊断时。
- 作者认为研究应聚焦于明确资源利用的潜在决定因素、超额费用来源,以及开发具有成本效益的诊断检查。
研究设计与样本
- 研究为基于OptumLabs Data Warehouse大型全国行政理赔数据库的真实世界数据分析,该数据库包含超过1亿名参加私人保险和Medicare Advantage健康计划的个体的纵向健康数据。
- 研究识别了2010—2014年间首次出现NAFLD理赔的152,064名成人,其中108,420人按年龄、性别、代谢共病、随访时长、诊断年份、种族、地理区域和保险类型与无NAFLD的同期对照1:1匹配。
- 最终研究队列共216,840人,中位年龄55岁(范围18—86岁),53%为女性,78%为白人,中位随访时间2.6年(范围1—6.5年)。
主要发现
- 有私人保险的NAFLD患者初次诊断时人均年总费用为7,804美元(四分位距[IQR]3,068—18,688美元),长期管理为3,789美元(IQR 1,176—10,539美元)。
- 有相似代谢共病但无NAFLD的匹配对照人均年总费用为2,298美元(IQR 681—6,580美元),NAFLD患者费用显著高于对照。
- 与对照相比,NAFLD患者医疗资源利用增幅最大的项目为肝活检(相对危险度[RR]=55.00,95%置信区间[CI]24.48—123.59)、影像检查(RR=3.95,95%CI 3.77—4.15)和住院(RR=1.87,95%CI 1.73—2.02)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing. The health care burden resulting from the multidisciplinary management of this complex disease is unknown. We assessed the total health care cost and resource utilization associated with a new NAFLD diagnosis, compared with controls with similar comorbidities. We used OptumLabs Data Warehouse, a large national administrative claims database with longitudinal health data of over 100 million individuals enrolled in private and Medicare Advantage health plans. We identified 152,064 adults with a first claim for NAFLD between 2010 and 2014, of which 108,420 were matched 1:1 by age, sex, metabolic comorbidities, length of follow-up, year of diagnosis, race, geographic region, and insurance type to non-NAFLD contemporary controls from the OptumLabs Data Warehouse database. Median follow-up time was 2.6 (range 1-6.5) years. The final study cohort consisted of 216,840 people with median age 55 (range 18-86) years, 53% female, 78% white. The total annual cost of care per NAFLD patient with private insurance was $7,804 (interquartile range [IQR] $3,068-$18,688) for a new diagnosis and $3,789 (IQR $1,176-$10,539) for long-term management. These costs are significantly higher than the total annual costs of $2,298 (IQR $681-$6,580) per matched control with similar metabolic comorbidities but without NAFLD. The largest increases in health care utilization that may account for the increased costs in NAFLD compared with controls are represented by liver biopsies (relative risk [RR] = 55.00, 95% confidence interval [CI] 24.48-123.59), imaging (RR = 3.95, 95% CI 3.77-4.15), and hospitalizations (RR = 1.87, 95% CI 1.73-2.02). Conclusion: The costs associated with the care for NAFLD independent of its metabolic comorbidities are very high, especially at first diagnosis. Research efforts shouldfocus on identification of underlying determinants of use, sources of excess cost, and development of cost-effective diagnostic tests.
引用
- Allen AM, Van Houten HK, Sangaralingham LR, et al. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database. Hepatology. 2018. PMID: 29774589. doi:10.1002/hep.30094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。